BLUEJET2024-04-012024-06-30 BLUEJET2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member BLUEJET2024-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544009 BLUEJET NOTLISTED Blue Jet Healthcare Limited Equity 2024-04-01 2025-03-31 2024-08-06 2024-07-31 INR Millions First quarter 11:50:00 12:20:00 2024-08-06 2024-08-06 Not applicable Single segment Pharmaceutical and API'S 2024-04-01 2024-06-30 Unaudited Standalone 1628990000.00 87150000.00 1716140000.00 908950000.00 0.00 -170810000.00 147810000.00 270000.00 34820000.00 300410000.00 1221450000.00 494690000.00 0.00 494690000.00 97500000.00 19420000.00 116920000.00 0.00 377770000.00 0.00 0.00 0.00 0.00 377770000.00 0.00 377770000.00 0.00 0.00 346930000.00 2 2.18 2.18 0.00 0.00 2.18 2.18 0.00 0.00 0.00 1. The above financial results of the Company for the three months ended June 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 06, 2024. Further, the above financial results have been reviewed by the Statutory Auditor of the Company. 2. The company is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products. 3. During the previous year, an incident at the Mahad facility resulted in a loss of damaged assets and compensation to employees aggregating to Rs. 97.43 million, accounted for as an exceptional items by the Company. 4. During the quarter ended June 30, 2024, the Company changed its method of depreciation from the Written Down Value (WDV) to the Straight-Line Method (SLM) based on the assessment of technical parameters of the said property plant & equipment, which indicates a more uniform consumption of economic benefits over time. Consequently, for the quarter ended June 30, 2024 the depreciation expense is lower by and profit before tax is higher by Rs. 35.33 million. 5. The results for the three months ended March 31, 2024 are balancing figure between the audited financial statements for the financial year ended March 31, 2024 and published unaudited results for nine months ended December 31, 2023. Other Expenses 300410000.00 0.00 0.00